Avoro Capital Advisors LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001633313

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 29 positions · Total reported value $9.67B · Top-10 concentration 83.5% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 62.1% · 3 new · 15 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -15.9% · vs SPY -18.0% · Prev Value $11.14B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -0.4% · vs SPY -2.6% · Latest Value $9.67B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Avoro Capital Advisors LLC disclosed 29 equity positions with a combined reported value of $9.67B. The filing implies a focused portfolio: its ten largest positions account for 83.5% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were UTHR ($1.49B), ASND ($1.15B), KRYS ($960.73M). By sector, the heaviest allocations are Health Care 99.6%, Other 0.4%.

Versus the prior quarter, Avoro Capital Advisors LLC opened 3 new positions, trimmed 15 and fully exited 0, a turnover rate of 62.1% of positions. The portfolio's overlap with the prior quarter was 90% of names.

The largest new positions opened in Q3 2026 were ABVX ($48.32M), SYRE ($47.83M), BHVN ($36.71M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • ABVX ABIVAX SA · $48.32M
  • SYRE SPYRE THERAPEUTICS INC · $47.83M
  • BHVN BIOHAVEN LTD · $36.71M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest Avoro Capital Advisors LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-07-28 Buy Scribe Therapeutics, Inc. 7,905 $18.25 SEC filing
2026-07-24 Buy Scribe Therapeutics, Inc. 50,000 $22.31 SEC filing
2026-07-24 Buy Scribe Therapeutics, Inc. 2,333,333 $15.00 SEC filing

All insider transactions →

Fund Profile

Avoro Capital Advisors LLC is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 26 US equity positions with a combined value of $11.14B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-74391 (status: Approved), registered 2012-03-30
  • Regulatory AUM (Form ADV): $13.55B as of 2026-03-05
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 1 hedge funds
  • Website: avorocapital.com

Portfolio Structure

  • 26 positions · $11.14B reported value (Q2 2026)
  • Top 10 holdings = 79.5% of reported value
  • Largest position: UTHR (UNITED THERAPEUTICS CORP DEL) at 13.5%
  • Average position size: $428.32M

Sector Tilt

  • Health Care 99.7%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 2 new, 12 added, 3 reduced, 6 exited
  • 9 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund reduced exposure to multiple biotech/healthcare names (6 of top 10), suggesting cautiousness or profit-taking in a volatile sector, while maintaining core holdings. 2. Key moves: - Reduced: UTHR (-0.8% shares), ASND (-1.2%), ARWR (-3.1%), RVMD (-6.6%), CYTK (-2.0%), DFTX (-1.9%). - Held: KRYS, ARGX, MDGL, KYMR (no share changes). - Added: No top-10 additions (3 new positions not listed). 3. Portfolio structure: Active, concentrated (29 positions), heavily biased toward Health Care (100% of top 10), with high risk (small/mid-cap biotech focus). 4. Per-holding one-liner: - UTHR: Pulmonary hypertension drugs (United Therapeutics). - ASND: Growth disorders therapy (Ascendis Pharma). - KRYS: Gene therapy for rare diseases (Krystal Biotech). - ARGX: Autoimmune/immunology drugs (Argenx). - MDGL: NASH/fatty liver drugs (Madrigal Pharmaceuticals). - KYMR: Dermatology/innate immunity drugs (Kymera Therapeutics). - ARWR: RNA therapeutics (Arrowhead Pharmaceuticals). - RVMD: Cancer/RAS pathway drugs (Revolution Medicines). - CYTK: Cardiomyopathy drugs (Cytokinetics). - DFTX: Gene therapy platform (Definium Therapeutics). 5. Style summary: Biotech-focused active manager trimming speculative positions while retaining core clinical-stage drug developers.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 03:55

Sector Allocation

Health Care 99.6%
Other 0.4%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 2.76M $1.49B 15.45%
15.45%
Reduce
2 5.05M $1.15B 11.90%
11.90%
Reduce
3 2.89M $960.73M 9.94%
9.94%
Hold
4 1.00M $958.91M 9.92%
9.92%
Hold
5 1.83M $923.93M 9.56%
9.56%
Hold
6 7.47M $835.60M 8.64%
8.64%
Hold
7 11.00M $719.95M 7.45%
7.45%
Reduce
8 2.15M $440.28M 4.55%
4.55%
Reduce
9 4.90M $322.96M 3.34%
3.34%
Reduce
10 7.05M $268.32M 2.78%
2.78%
Reduce
11 6.56M $204.99M 2.12%
2.12%
Hold
12 5.50M $204.54M 2.12%
2.12%
Reduce
13 5.63M $181.95M 1.88%
1.88%
Reduce
14 6.73M $162.54M 1.68%
1.68%
Hold
15 1.50M $119.28M 1.23%
1.23%
Reduce
16 23.89M $116.34M 1.20%
1.20%
Hold
17 12.38M $94.96M 0.98%
0.98%
Reduce
18 3.78M $80.50M 0.83%
0.83%
Hold
19 1.89M $58.36M 0.60%
0.60%
Reduce
20 2.50M $51.48M 0.53%
0.53%
Hold
21 1.30M $50.87M 0.53%
0.53%
Reduce
22 488.00K $48.32M 0.50%
0.50%
New
23 2.60M $47.83M 0.49%
0.49%
New
24 1.41M $41.93M 0.43%
0.43%
Reduce
25 1.77M $41.56M 0.43%
0.43%
Reduce
26 2.75M $36.71M 0.38%
0.38%
New
27 2.38M $36.45M 0.38%
0.38%
Add
28 2.85M $10.71M 0.11%
0.11%
Hold
29 525.00K $1.77M 0.02%
0.02%
Reduce

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 90% R 90% F1 90% (modelled on 2026-Q2; 9/10 hit)

Low-confidence forecast This fund replaces about 25% of its Top-10 each quarter and backtests at F1 78% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (11 quarters)

Avg precision 78% · recall 78% · F1 78% · avg rank error 1.8 · Top-10 turnover 25%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 90% 90% 90% APLS · UTHR · ARGX · ASND · MDGL · SRPT · BMRN · XBI · FOLD · CERE UTHR · APLS · ASND · SRPT · MDGL · ARGX · KRYS · XBI · BMRN · FOLD
2024-Q2 100% 100% 100% UTHR · APLS · ASND · SRPT · MDGL · ARGX · KRYS · XBI · BMRN · CERE UTHR · MDGL · ASND · ARGX · SRPT · KRYS · APLS · BMRN · CERE · XBI
2024-Q3 80% 80% 80% UTHR · MDGL · ASND · ARGX · SRPT · KRYS · APLS · BMRN · CERE · RNAM UTHR · ASND · ARGX · KRYS · MDGL · APLS · SRPT · RNAM · FOLD · ITCI
2024-Q4 80% 80% 80% UTHR · ASND · ARGX · KRYS · MDGL · RNAM · APLS · SRPT · FOLD · ITCI UTHR · ARGX · ASND · MDGL · KRYS · APLS · SRPT · ITCI · VERA · XENE
2025-Q1 70% 70% 70% UTHR · ARGX · ASND · MDGL · KRYS · APLS · SRPT · ITCI · VERA · XENE UTHR · ASND · ARGX · MDGL · KRYS · BPMC · APLS · RNAM · XENE · SLNO
2025-Q2 80% 80% 80% ASND · UTHR · ARGX · MDGL · KRYS · BPMC · APLS · RNAM · XENE · KYMR ASND · UTHR · ARGX · MDGL · KRYS · KYMR · APLS · RNAM · MLTX · AKRO
2025-Q3 70% 70% 70% ASND · UTHR · ARGX · MDGL · KRYS · KYMR · APLS · AKRO · MLTX · RNAM ASND · MDGL · ARGX · KRYS · ARWR · KYMR · MRUS · RNAM · APLS · CNTA
2025-Q4 70% 70% 70% ASND · MDGL · ARGX · KRYS · ARWR · KYMR · MRUS · RNAM · CNTA · QURE UTHR · MDGL · ARGX · KRYS · ARWR · KYMR · GPCR · RNAM · CNTA · CELC
2026-Q1 70% 70% 70% UTHR · MDGL · ARGX · KRYS · ARWR · KYMR · GPCR · CNTA · RNAM · CELC ASND · MDGL · KRYS · ARGX · ARWR · KYMR · APLS · CNTA · XENE · GPCR
2026-Q2 60% 60% 60% ASND · MDGL · KRYS · ARGX · ARWR · KYMR · APLS · CNTA · GPCR · XENE UTHR · ASND · KRYS · MDGL · ARGX · ARWR · KYMR · RVMD · CYTK · CELC
2026-Q3 ★ 90% 90% 90% UTHR · ASND · KRYS · MDGL · ARGX · ARWR · KYMR · CYTK · RVMD · CELC UTHR · ASND · KRYS · ARGX · MDGL · KYMR · ARWR · RVMD · CYTK · DFTX

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-13. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-13 Trading days32 Holdings6 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-13, and will update as prices arrive.

Portfolio return-4.22%Buy & hold
QQQ synthetic benchmark-13.72%Liquidity weighted
Excess return+9.50%vs benchmark
Barra annualised vol29.7%Model estimate
Realised vol33.0%Annualised in window
Weighted beta0.40Raw exposure
Factor / specific risk52% / 48%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)78.485.091.798.3105.010-0110-2311-13Avoro Capital Advisors LLCQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)-4.22%Disclosed long book
QQQ synthetic benchmark-13.72%Liquidity-weighted constituents
Model universe, equal weight+0.30%Opportunity-cost reference
Excess return+9.50%Portfolio − benchmark
Arithmetic return sum-3.63%Difference vs compounded is the cross term
Weighted raw beta0.40Weighted holding betas
Realised volatility (annualised)32.98%Daily returns in window
Barra model volatility (annualised)29.68%Factor + specific
Factor share of variance52.2%Barra factors
Specific share of variance47.8%Stock residuals
Reported value$4.14B13F long US equity

2. Return attribution

The -3.63% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 +3.35% 92.3%
Momentum & Growth 3 -2.57% -70.8%
Volatility & Tail Risk 7 +3.78% 103.9%
Industry 12 +8.12% 223.5%
Specific 1 -16.31% -448.8%
Return attribution (style + industry, %)-10.6-5.3+0.0+5.3+10.6Mid Cap-0.58Leverage (Downside Vol)+0.58Growth-0.65Max Drawdown-0.67Historical Volatility-0.99Non-linear Size+1.00Turnover+1.27Size+2.07Momentum-2.08Beta-2.34Residual Volatility+2.87Skewness-5.53Health Care+8.12Kurtosis+9.85
Factor Type Exposure Factor return Contribution Share of |return|
Kurtosis Style +1.41 +6.97% +9.85% 271.1%
Health Care Industry +1.00 +8.12% +8.12% 223.5%
Residual Volatility Style +1.08 +2.66% +2.87% 78.9%
Size Style -1.13 -1.83% +2.07% 56.9%
Turnover Style -0.27 -4.77% +1.27% 34.9%
Non-linear Size Style +1.10 +0.91% +1.00% 27.6%
Leverage (Downside Vol) Style -0.32 -1.82% +0.58% 15.9%
Short-term Reversal Style +0.19 +0.79% +0.15% 4.2%
Amihud Illiquidity Style +1.11 -0.40% -0.45% -12.3%
Mid Cap Style +0.34 -1.69% -0.58% -15.8%
Growth Style -0.41 +1.57% -0.65% -17.9%
Max Drawdown Style +0.34 -1.96% -0.67% -18.3%
Historical Volatility Style +0.08 -12.86% -0.99% -27.4%
Momentum Style +0.62 -3.34% -2.08% -57.1%
Beta Style -0.48 +4.85% -2.34% -64.3%
Skewness Style +1.31 -4.21% -5.53% -152.0%
Specific Specific — — -16.31% -448.8%

3. Risk attribution

Annualised volatility is 29.68%; factor risk explains 52.2% of variance and specific risk 47.8%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-51.6-25.8+0.0+25.8+51.6Max Drawdown-1.74Leverage (Downside Vol)-1.31Residual Volatility-1.10Short-term Reversal-0.59Mid Cap+0.48Amihud Illiquidity+2.09Beta+2.11Growth+2.48Momentum+4.16Kurtosis+4.27Size+6.15Skewness+9.18Health Care+26.28Specific+47.75
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 47.8% +14.17% 14.2%
Health Care Industry +1.00 26.3% +7.80% 7.8%
Skewness Style +1.31 9.2% +2.72% 2.7%
Size Style -1.13 6.2% +1.82% 1.8%
Kurtosis Style +1.41 4.3% +1.27% 1.3%
Momentum Style +0.62 4.2% +1.23% 1.2%
Growth Style -0.41 2.5% +0.74% 0.7%
Beta Style -0.48 2.1% +0.62% 0.6%
Amihud Illiquidity Style +1.11 2.1% +0.62% 0.6%
Mid Cap Style +0.34 0.5% +0.14% 0.1%
Short-term Reversal Style +0.19 -0.6% -0.18% -0.2%
Residual Volatility Style +1.08 -1.1% -0.33% -0.3%
Leverage (Downside Vol) Style -0.32 -1.3% -0.39% -0.4%
Max Drawdown Style +0.34 -1.7% -0.52% -0.5%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-1.5-0.50.51.52.4Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -1.13 +2.10 -3.23
Non-linear Size +1.10 +1.68 -0.58
Mid Cap +0.34 +0.13 +0.21
Beta -0.48 +1.29 -1.78
Momentum +0.62 +0.72 -0.09
Short-term Reversal +0.19 -0.64 +0.83
Residual Volatility +1.08 -0.40 +1.48
Historical Volatility +0.08 +0.86 -0.78
Liquidity +0.17 +0.11 +0.06
Amihud Illiquidity +1.11 +1.16 -0.05
Turnover -0.27 +0.21 -0.47
Growth -0.41 +0.58 -1.00
Leverage (Downside Vol) -0.32 +0.14 -0.46
Skewness +1.31 +0.24 +1.07
Kurtosis +1.41 +0.21 +1.20
Max Drawdown +0.34 -0.08 +0.42

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -19.18% +4.32% +14.12% -14.12% +14.12%
Communication Services 0.0% 2.6% +0.00% -15.54% +0.06% +0.41% -0.41% +0.41%
Utilities 0.0% 0.8% +0.00% +11.58% -0.20% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.58% -0.24% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +5.56% -1.66% -0.49% +0.49% -0.49%
Industrials 0.0% 11.1% +0.00% +7.16% -2.27% -0.80% +0.80% -0.80%
Health Care 100.0% 1.7% -4.02% +9.16% +22.08% -0.23% -12.96% -4.18%
Total +21.99% +12.76% -25.94% +8.80%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
UTHR UNITED THERAPEUTICS CORP DEL Health Care 36.09% +9.09% +3.28% Reduce
ARGX ARGENX SE Health Care 23.18% +0.12% +0.03% Hold
MDGL MADRIGAL PHARMACEUTICALS INC Health Care 22.33% -15.19% -3.39% Hold
RVMD REVOLUTION MEDICINES INC Health Care 10.64% -16.06% -1.71% Reduce
GPCR STRUCTURE THERAPEUTICS INC Health Care 4.95% -36.04% -1.79% Hold
TSHA TAYSHA GENE THERAPIES INC Health Care 2.81% -15.81% -0.45% Hold
Contribution rank Symbol Sector Weight Return Contribution
1 UTHR Health Care 36.09% +9.09% +3.28%
2 ARGX Health Care 23.18% +0.12% +0.03%
3 TSHA Health Care 2.81% -15.81% -0.45%
4 RVMD Health Care 10.64% -16.06% -1.71%
5 GPCR Health Care 4.95% -36.04% -1.79%
6 MDGL Health Care 22.33% -15.19% -3.39%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-13 (32 trading days), the reported portfolio returned -4.22%, versus -13.72% for the QQQ synthetic benchmark — an excess of +9.50%.
  2. Return attribution: the largest positive style/industry contributions came from Kurtosis +9.85%, Health Care +8.12%, Residual Volatility +2.87%; the largest drags came from Skewness -5.53%, Beta -2.34%, Momentum -2.08%. Specific (stock-level) return contributed -16.31%.
  3. Risk attribution: Barra model volatility is 29.68% annualised; factor risk explains 52% of variance and specific risk 48%. The largest factor risk sources are Health Care 26.3%, Skewness 9.2%, Size 6.2%.
  4. Style tilt: size -1.13, momentum +0.62, volatility +0.08, liquidity +0.17; the weighted raw beta is 0.40. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +21.99%, selection +12.76% and interaction -25.94%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did Avoro Capital Advisors LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, Avoro Capital Advisors LLC reported 29 equity positions worth $9.67B in aggregate; its largest disclosed positions were UTHR ($1.49B), ASND ($1.15B), KRYS ($960.73M).

How large is Avoro Capital Advisors LLC's portfolio?

Avoro Capital Advisors LLC reported $9.67B of long equity holdings across 29 positions as of 2026-Q3. Top-10 holdings account for 83.5% of reported value.

What is Avoro Capital Advisors LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/avoro-capital-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →